Printer Friendly

EPIGEN ANNOUNCES PROGRAM FOR NEW PROSTATE CANCER TISSUE STAINING TEST

 WELLESLEY, Mass., July 27 /PRNewswire/ -- Epigen, Inc. (AMEX/ECM: EPN.EC), has successfully demonstrated the ability of its proprietary monoclonal antibodies to differentiate benign from malignant prostatic cancer. The company announced today that it is commercializing this unique property as a staining test to be used by pathologists to determine whether or not the patient has cancer. Presently, there are no products that can satisfactorily make this diagnosis.
 James Mongiardo, president of Epigen, said that "the basis for this new program derives from research conducted at the Columbia Presbyterian Medical Center in New York, examining carcinoma and normal human tissue for Epigen's proprietary Human Carcinoma Antigen (HCA)." John F. Codington, Ph.D., Harvard Medical School and a member of Epigen's Scientific Advisory Board, discovered HCA, which is a mucin glycoprotein. It is generally found in large quantities on the cell membranes of carcinomas (malignant tumors) but not in normal tissue.
 When the HCA monoclonal antibody with a stain is placed on prostate cancer and benign prostatic hyperplasia tissue, a non-cancerous condition of the prostate, the cancerous tissue is clearly stained. It does not stain benign or normal tissue.
 Epigen has initiated a program to expedite the commercialization of this kit, which will be used by pathologists. It is expected that this kit will be commercially available in the fourth quarter. No regulatory approvals are required for this type of product.
 Epigen, Inc., is a biopharmaceutical company organized to develop and commercialize products for use in the monitoring, diagnosis and treatment of cancer.
 -0- 7/27/93
 /CONTACT: James F. Mongiardo, president of Epigen, 617-237-9102; or William Doyle of Strategic Marketing Systems, 212-888-3883, for Epigen/
 (EPN.EC)


CO: Epigen, Inc. ST: Massachusetts IN: MTC SU: PDT

GK-MG -- NY001 -- 6062 07/27/93 08:50 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:294
Previous Article:DATA GENERAL REPORTS THIRD QUARTER RESULTS
Next Article:ELAN REPORTS FIRST QUARTER EARNINGS UP 69 PERCENT
Topics:


Related Articles
EPIGEN FILES FOR U.S. PATENT ON HUMAN CARCINOMA ANTIGEN
EPIGEN REPORTS QUARTER FINANCIAL RESULTS
EPIGEN REPORTS SECOND QUARTER FINANCIAL RESULTS; COMPANY SCIENTISTS TO PRESENT DATA AT INTERNATIONAL GLYCOCONJUGATE SYMPOSIUM
EPIGEN SCIENTISTS PRESENT CHARACTERIZATION OF HUMAN CARCINOMA ANTIGEN CANCER MARKER & COD TEST DATA TO INTERNATIONAL GLYCOCONJUGATE SYMPOSIUM
EPIGEN COMPLETES BREAST CANCER MONITORING 'COD-TEST'
EPIGEN ANNOUNCES RESULTS OF COD TEST TRIAL
NEW TEST FROM HORUS THERAPEUTICS FOR MORE ACCURATE DETECTION OF PROSTATE CANCER
Cytogen and Bostwick Laboratories to Develop PSMA Tissue Staining Facility.
Epigen, Inc. Announces the Hiring of Ortho's Former Vice President of Research.
Medarex and Epigen Form Antibody Collaboration.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters